Safety and Efficacy of Esketamine - Dexmedetomidine Combination Versus Dexmedetomidine Monotherapy for Hyperactive Delirium in ICU Patients on Non-Invasive Respiratory Support (SEED-NIRS Trial): Study Protocol of a Randomized Controlled Trial
Key facts
- Who runs it
- The First Affiliated Hospital with Nanjing Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 356 people, planned
- Started
- 28 Sept 2026
- Expected to end
- 1 Jan 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Esketamine combined with dexmedetomidine
- Dexmedetomidine
- Record updated
- 3 September 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Age ≥18 years and ≤80 years at the time of randomization
- Hospitalized in the ICU (with an expected ICU stay >24 hours)
- Patients with hyperactive delirium: meeting criteria for Confusion Assessment Method for the ICU (CAM-ICU)[19] positivity (i.e., acute onset or fluctuating course plus inattention, and at least one secondary criterion-disorganized thinking or altered level of consciousness) and having agitation which is diagnosed if the Richmond Agitation-Sedation Scale (RASS) score[20] is superior or equal to +1. (The RASS and CAM-ICU are used to assess sedation and delirium levels. Hyperactive delirium is defined as CAM-ICU positive with RASS > +1)
- Receiving non-invasive respiratory support (eg. high-flow nasal cannula, CPAP, or non-invasive ventilation) at least for >24 hours
Who cannot take part
- Recent administration of esketamine, dexmedetomidine or haloperidol within previous 72 hours
- Patients receiving non-invasive respiratory support via a tracheostomy
- Known or suspected allergy or Contraindications to any of the study drugs
- Conditions that may affect efficacy assessment or cognitive function testing, such as blindness, deafness, aphasic, or coma patients
- History of epilepsy or seizures
- Neuropsychiatric conditions per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) that may introduce bias (e.g., active substance use disorder, psychosis, etc.), including alcoholism, drug abuse, or use of psychotropic medications
- Severe hepatic insufficiency (Child-Pugh grade C)
- A history of sleep disorders requiring medical intervention within the past month
- Other conditions deemed unsuitable for inclusion by the investigators
- Severe arrhythmias (e.g., ventricular fibrillation, second- or third-degree atrioventricular block, sick sinus syndrome, ventricular tachycardia, QTc interval ≥470 ms, severe bradycardia (heart rate <40 beats per minute), etc.), or left ventricular ejection fraction (LVEF) <30%
- Severe renal dysfunction, defined as: chronic renal insufficiency with a glomerular filtration rate (GFR) ≤ 29 mL/min/1.73 m²; or subjects on long-term maintenance hemodialysis or peritoneal dialysis
- Pregnancy or lactation
- Patients with an estimated survival period of less than 48 hours as judged by the investigator
- Patients with untreated or inadequately treated hyperthyroidism
- Patients or their legally authorized representatives (family members) who are unable to cooperate or unwilling to provide written informed consent
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This investigator-initiated, randomized, controlled, single-blind, superiority trial aims to assess the efficacy and safety of esketamine combined with dexmedetomidine for the management of agitation or delirium in intensive care unit (ICU) patients receiving non-invasive respiratory support. The primary endpoint is a clinically prioritized hierarchical composite endpoint within 28 days, including intubation or tracheostomy, delirium duration, and agitation duration.
The 2 groups in the trial
- Esketamine combined with dexmedetomidineTreatment being tested
Participants will receive esketamine at 0.125-0.20 mg/(kg·h) combined with dexmedetomidine at 0.2-0.5 μg/kg/h. Sedation will be targeted to maintain a RASS score between -1 and +1, prioritizing light sedation while ensuring adequate control of agitation. Drug titration will follow a protocolized, stepwise approach to minimize inter-physician variability: * If RASS ≥ +2, the esketamine infusion rate will be preferentially increased within the predefined range. * If agitation persists at the upper esketamine dose, dexmedetomidine may be increased within its allowed range. * If RASS between -1 and +1, the current dose will be maintained. * If RASS ≤ -2, esketamine will be reduced or temporarily discontinued first, followed by reduction of dexmedetomidine if necessary.
- DexmedetomidineExisting treatment, for comparison
Participants will receive dexmedetomidine at 0.2-0.5 μg/kg/h. Sedation will be targeted to maintain a Richmond Agitation-Sedation Scale (RASS) score between -1 and +1, prioritizing light sedation while ensuring adequate control of agitation. Drug titration will follow a protocolized, stepwise approach to minimize inter-physician variability: * If RASS ≥ +2, dexmedetomidine infusion will be increased within the predefined range. * If RASS ≤ -2, dexmedetomidine will be reduced or temporarily discontinued. Continuous infusion will be maintained for at least 36 hours after resolution of delirium, or until ICU discharge if earlier, to reduce the risk of relapse.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Efficacy of Esketamine - Dexmedetomidine Combination Versus Dexmedetomidine Monotherapy for Hyperactive Delirium in ICU Patients on Non-Invasive Respiratory Support (ESSENTIAL Trial): Study Protocol of a Randomized Controlled Trial
- Criteria questions
- Built from NCT07377981, who can take part
- Record updated
- 3 September 2026